Wells Fargo analyst Derek Archila upgraded C4 Therapeutics (CCCC) to Overweight from Equal Weight with a price target of $12, up from $8. The shares “are cheap” and Wells is now more confident in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback